IXAZOMIB

Main information

  • Trade name:
  • IXAZOMIB Capsule, hard 3MG
  • Dosage:
  • 3MG
  • Pharmaceutical form:
  • Capsule, hard
  • Administration route:
  • Oral use
  • Units in package:
  • 3 Blister
  • Prescription type:
  • on prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • IXAZOMIB Capsule, hard 3MG
    Czech Republic
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • IXAZOMIB
  • Product summary:
  • IXAZOMIB

Other information

Status

  • Source:
  • SUKL - Státní ústav pro kontrolu léčiv
  • Authorization number:
  • F - specific therapeutic programme
  • Last update:
  • 22-06-2017

26-7-2018

Opinion/decision on a Paediatric investigation plan (PIP):    Ninlaro, Ixazomib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): Ninlaro, Ixazomib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

10-7-2018

Ninlaro (Takeda Pharma A/S)

Ninlaro (Takeda Pharma A/S)

Ninlaro (Active substance: ixazomib) - Centralised - Yearly update - Commission Decision (2018)4463 of Tue, 10 Jul 2018

Europe -DG Health and Food Safety